Kronos Bio Aktie - KRON

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

0,9107

Gebot

0,9107

Fragen

0,9316

Volumen

36.014

0,9107 Tagesbereich 0,9525

0,69 52-Wochen-Bereich 1,60

Marktkapitalisierung

54,952M

Handelsende

0,95

Handelsbeginn

0,95

Letzte Trade

100

0.9107

Letzter Handelszeitpunkt

15:50:14

Finanzvolumen

US$ 33.700

VWAP

0,935746

Durchschnittliches Volumen (3 Mio.)

239.754

Ausgegebene Aktien

60.340.918

Dividendenrendite

Kurs-Gewinn-Verhältnis

-0,50

Gewinn pro Aktie (EPS)

-1,87

Erlöse

6,29M

Nettogewinn

-112,67M

Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.kronosbio.com

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Kronos Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KRON. The last closing price for Kronos Bio was US$0,95. Over the last year, Kronos Bio shares have traded in a share price range of US$ 0,69 to US$ 1,60.

Kronos Bio currently has 60.340.918 shares in issue. The market capitalisation of Kronos Bio is US$57,32 million. Kronos Bio has a price to earnings ratio (PE ratio) of -0.50.

Kronos Bio Announces CEO Transition and Reduction in Force

– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman...

Form EFFECT - Notice of Effectiveness

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory...

Form 8-K - Current report

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

– Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant...

Form S-3 - Registration statement under Securities Act of 1933

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

– Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong...

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a...

Form 4 - Statement of changes in beneficial ownership of securities

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.0143	-1.54594594595	0.925	0.989999	0.9031	197661	0.95377859	CS
4	-0.0393	-4.13684210526	0.95	1.04	0.9031	180678	0.97934547	CS
12	-0.0393	-4.13684210526	0.95	1.07	0.8902	239754	0.97014082	CS
26	-0.0693	-7.07142857143	0.98	1.09	0.8	205420	0.95512413	CS
52	-0.4393	-32.5407407407	1.35	1.6	0.69	270567	1.01981081	CS
156	-6.3293	-87.4212707182	7.24	8.42	0.69	290076	2.12900784	CS
260	-27.3793	-96.7808412867	28.29	39.605	0.69	278084	7.96452241	CS

KRON - Frequently Asked Questions (FAQ)

What is the current Kronos Bio share price?

The current share price of Kronos Bio is US$ 0,9107

How many Kronos Bio shares are in issue?

Kronos Bio has 60.340.918 shares in issue

What is the market cap of Kronos Bio?

The market capitalisation of Kronos Bio is USD 57,32M

What is the 1 year trading range for Kronos Bio share price?

Kronos Bio has traded in the range of US$ 0,69 to US$ 1,60 during the past year

What is the PE ratio of Kronos Bio?

The price to earnings ratio of Kronos Bio is -0,5

What is the cash to sales ratio of Kronos Bio?

The cash to sales ratio of Kronos Bio is 9,02

What is the reporting currency for Kronos Bio?

Kronos Bio reports financial results in USD

What is the latest annual turnover for Kronos Bio?

The latest annual turnover of Kronos Bio is USD 6,29M

What is the latest annual profit for Kronos Bio?

The latest annual profit of Kronos Bio is USD -112,67M

What is the registered address of Kronos Bio?

The registered address for Kronos Bio is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Kronos Bio website address?

The website address for Kronos Bio is www.kronosbio.com

Which industry sector does Kronos Bio operate in?

Kronos Bio operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SYRSSyros Pharmaceuticals Inc	US$ 0,2201 (140,28%)	480,61M
TSVT2seventy bio Inc	US$ 4,93 (76,07%)	23,02M
BHATBlue Hat Interactive Entertainment Technology	US$ 0,0544 (62,39%)	171,39M
RAYRaytech Holding Ltd	US$ 1,34 (54,02%)	16,54M
CUTRCutera Inc	US$ 0,1849 (43,89%)	172,48M
ARVNArvinas Inc	US$ 8,15 (-53,59%)	7,36M
LZMHLZ Technology Holdings Ltd	US$ 7,56 (-51,72%)	281,27k
SPGCSacks Parente Golf Inc	US$ 0,1038 (-35,17%)	19,41M
BDRXBiodexa Pharmaceuticals PLC	US$ 2,0399 (-28,42%)	464,86k
XAGELongevity Health Holdings Inc	US$ 0,235 (-26,56%)	1,68M
SYRSSyros Pharmaceuticals Inc	US$ 0,2202 (140,39%)	473,8M
CUTRCutera Inc	US$ 0,182 (41,63%)	171,46M
BHATBlue Hat Interactive Entertainment Technology	US$ 0,054701 (63,29%)	171M
AWHAspira Womans Health Inc	US$ 0,2562 (29,39%)	161,16M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 7,435 (0,75%)	134,77M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Kronos Bio Inc (KRON) Börsenkurse

Kronos Bio Inc (KRON)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Kronos Bio Inc

KRON Neueste Nachrichten

Kronos Bio Announces CEO Transition and Reduction in Force

Form EFFECT - Notice of Effectiveness

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

Form 8-K - Current report

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

Form S-3 - Registration statement under Securities Act of 1933

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Kronos Bio Announces CEO Transition and Reduction in Force

Form EFFECT - Notice of Effectiveness

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

Form 8-K - Current report

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

Form S-3 - Registration statement under Securities Act of 1933

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

KRON - Frequently Asked Questions (FAQ)

Beweger

KRON Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen